港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

670.135

+9.6471.46%

漲家數：17

跌家數：13

平家數：4

市盈率：- -

高：678.126

開：660.587

低：657.123

收：660.489

成交量：1.54億

成交額：46.33億

市值：4,299.47億

流通市值：3,802.52億

資料載入中...

總覽新聞資訊

創新藥概念午後再度活躍海創藥業升逾11%

每日经济新闻

2026年一季度創新藥BD交易突破600億美元！恒生創新藥ETF華泰柏瑞（520500）成交額顯著放量

加科思－Ｂ(01167)股價下跌5.125%，現價港幣$6.85

阿斯达克财经

德琪醫藥－Ｂ(06996)股價下跌5.112%，現價港幣$4.64

阿斯达克财经

貝康醫療2025業績亮點：從IVD到IVF全場景AI平台，成為中國輔助生殖領域行業龍頭

盈利33倍，和鉑醫藥憑什麼成為「確定性資產」？

榮昌生物(09995)出現大手賣出5.35萬股，成交價$95.0，涉資508.25萬

阿斯达克财经

港股異動 | 醫藥外包概念走強，昭衍新藥績後升逾13%，凱萊英升逾11%

老虎资讯综合

A股開盤速遞 | 三大指數升跌不一白酒板塊快速拉升創新藥概念反覆活躍

智通财经网

貝康醫療-B(02170)發布年度業績，收入2.33億元核心產品註冊、國產化推進及平台型業務佈局方面取得多項重要進展

微創心通-B(02160)發布年度業績股東應占虧損1881.9萬元按年擴大170.85%

華昊中天醫藥-B(02563)股份全流通獲聯交所授出上市批准

《業績》開拓藥業(09939.HK)全年虧損擴至2億人民幣

阿斯达克财经

康希諾生物(06185)公布2025年業績實現收入約10.59億元按年增長28.43%

和鉑醫藥-B(02142)公布2025年業績税後溢利9222.1萬美元按年增長約32.63倍

億騰嘉和(06998)3月30日斥資65.88萬港元回購25.45萬股

歐康維視生物-B(01477)：OT-211 III期臨床試驗完成首例患者入組

和鉑醫藥-B公布2025財年業績：持續全球合作夯實長期增長根基

和鉑醫藥公布2025年度業績：常態化全球合作構築業績增長基石

牛散趙建平連續重倉！創新藥迎來配置時點！

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":670.1354,"timestamp":1775117299351,"preClose":660.4887,"halted":0,"volume":153717417,"delay":0,"changeRate":0.014605,"floatShares":0,"shares":0,"eps":0,"marketStatus":"清明節翌日休市","change":9.646667,"latestTime":"04-02 16:00:00","open":660.58655,"high":678.1257,"low":657.12256,"amount":4633342498,"amplitude":0.031799,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"pbRate":5.274197,"peRate":-86.845688,"turnoverRate":0.005552,"increases":17,"decrements":14,"flats":2,"marketCap":429946652416,"floatMarketCap":380251567184},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":678.1257,"amplitude":0.031799,"preClose":660.4887,"low":657.12256,"pbRate":"5.274197","latestPrice":670.1354,"volume":153717417,"delay":0,"open":660.58655,"prevYearClose":556.26263,"prevWeekClose":670.135,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":579.36,"twentyDayClose":522.155,"sixtyDayClose":580.971,"secType":"PLATE","market":"HK","turnoverRate":0.005552,"peRate":-86.845688,"marketCap":429946652416,"floatMarketCap":380251567184,"timestamp":1775117299351,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":17,"down":13,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623308309","title":"創新藥概念午後再度活躍 海創藥業升逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623308309","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623308309?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 13:50","pubTimestamp":1774936200,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月31日，创新药概念午后再度活跃，海创药业涨超11%，此前津药药业、凯莱英涨停，双鹭药业、首药控股、亚太药业、威尔药业、万邦德、诚达药业跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690242481.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690242481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","159992","BK1574","06978","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623701133","title":"2026年一季度創新藥BD交易突破600億美元！恒生創新藥ETF華泰柏瑞（520500）成交額顯著放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2623701133","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623701133?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 13:36","pubTimestamp":1774935360,"startTime":"0","endTime":"0","summary":"今日早盘，创新药板块延续回暖态势，相关ETF交投火热。　　Wind数据显示，当前全市场仅有的跟踪恒生创新药指数的ETF产品——恒生创新药ETF华泰柏瑞成交额近期显著放量。2026年3月28日，据国家药监局发布信息显示，2026年一季度我国创新药BD交易总额已突破600亿美元，接近2025年全年总额的一半；交易数量达53件，首付款超33亿美元，规模与增速均创历史同期新高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-03-31/doc-inhswawe2210437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","520500","BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623370988","title":"加科思－Ｂ(01167)股價下跌5.125%，現價港幣$6.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2623370988","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623370988?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 13:15","pubTimestamp":1774934100,"startTime":"0","endTime":"0","summary":"[下跌股]加科思－Ｂ(01167) 股价在下午01:15比前收市价下跌5.125%，现股价为港币$6.85。至目前为止，今日最高价为$7.34，而最低价为$6.85。总成交量为127.23万股，总成交金额为港币$909.862万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603312197/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603312197/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623370985","title":"德琪醫藥－Ｂ(06996)股價下跌5.112%，現價港幣$4.64","url":"https://stock-news.laohu8.com/highlight/detail?id=2623370985","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623370985?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 13:15","pubTimestamp":1774934100,"startTime":"0","endTime":"0","summary":"[下跌股]德琪医药－Ｂ(06996) 股价在下午01:15比前收市价下跌5.112%，现股价为港币$4.64。至目前为止，今日最高价为$4.92，而最低价为$4.64。总成交量为164.95万股，总成交金额为港币$788.222万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603312199/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603312199/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","06996","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623377568","title":"貝康醫療2025業績亮點：從IVD到IVF全場景AI平台，成為中國輔助生殖領域行業龍頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2623377568","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623377568?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 12:49","pubTimestamp":1774932592,"startTime":"0","endTime":"0","summary":"伴随国产智造与人工智能的双重浪潮，贝康医疗正以确定的盈利预期和坚实的竞争壁垒，叩响辅助生殖赛道价值重估的大门。","market":"us","thumbnail":"https://img2.gelonghui.com/b17e2-5257232d-3843-4fee-aee1-cf4340bf53a5.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-5257232d-3843-4fee-aee1-cf4340bf53a5.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4247094","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02170","IVF","BK1597","AGIX","CHAT","BK4082","AIPO","BK1574","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623723953","title":"盈利33倍，和鉑醫藥憑什麼成為「確定性資產」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623723953","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623723953?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 12:09","pubTimestamp":1774930173,"startTime":"0","endTime":"0","summary":"和铂医药不再是一家赌临床数据的传统Biotech，而是一个掌握全球稀缺底层技术、具备常态化造血能力、与MNC深度绑定的“技术基建商”。","market":"sg","thumbnail":"https://img2.gelonghui.com/b17e2-c747d72b-9b53-4b59-8164-252fd1f5ff31.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-c747d72b-9b53-4b59-8164-252fd1f5ff31.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4246709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623372639","title":"榮昌生物(09995)出現大手賣出5.35萬股，成交價$95.0，涉資508.25萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2623372639","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623372639?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 11:53","pubTimestamp":1774929180,"startTime":"0","endTime":"0","summary":"[大手成交]荣昌生物(09995)在上午11:53出现大手卖出，成交量为5.35万，成交价为港币$95.0，涉资508.25万。至目前为止，股价跌3.844%，今日最高价为$101.4，而最低价为$95.0，总成交量为265.4万股，总成交金额港币$2.569亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603314836/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603314836/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2148510915.USD","BK0239","LU2328871848.SGD","688331","LU1064130708.USD","BK1574","LU1969619763.USD","LU1064131003.USD","BK1161","09995","LU2488822045.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109731579","title":"港股異動 | 醫藥外包概念走強，昭衍新藥績後升逾13%，凱萊英升逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109731579","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109731579?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 09:51","pubTimestamp":1774921897,"startTime":"0","endTime":"0","summary":"3月31日，医药外包概念走强，$昭衍新药(06127)$涨超13%，$凯莱英(06821)$涨超11%，$康龙化成(03759)$涨超6%，$药明生物(02269)$、$泰格医药(03347)$涨超5%","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","09939","BK1161","BK4588","BK1576","LU1328615791.USD","BK0216","BK1141","BK1515","06127","BK4585","06821","BK0239","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623376462","title":"A股開盤速遞 | 三大指數升跌不一 白酒板塊快速拉升 創新藥概念反覆活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=2623376462","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623376462?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 09:51","pubTimestamp":1774921872,"startTime":"0","endTime":"0","summary":"3月31日，A股沪指高开0.02%，深成指低开0.31%，创业板指低开0.80%。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260331/20260331095128_13566.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260331/20260331095128_13566.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1574","06978","159992","159982","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328501","title":"貝康醫療-B(02170)發布年度業績，收入2.33億元 核心產品註冊、國產化推進及平台型業務佈局方面取得多項重要進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328501","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623328501?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 01:24","pubTimestamp":1774891440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布截至2025年12月31日止年度业绩，该集团取得收入2.33亿元，同比减少22.01%;公司权益股东应占亏损2.23亿元，同比减少5.7%;每股亏损0.8元。2025年，对本集团而言，是由“研发及注册驱动”逐步迈向“商业化落地及经营优化驱动”的关键一年。报告期内，本集团在核心产品注册、国产化推进及平台型业务布局方面取得多项重要进展。于男科领域，家用精子检测设备获批上市，进一步完善本集团在辅助生殖前端检测场景的产品布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"贝康医疗-B(02170)发布年度业绩，收入2.33亿元 核心产品注册、国产化推进及平台型业务布局方面取得多项重要进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1597","BK1222","02170","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623340317","title":"微創心通-B(02160)發布年度業績 股東應占虧損1881.9萬元 按年擴大170.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623340317","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623340317?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:48","pubTimestamp":1774889327,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微创心通-B(02160)发布截至2025年12月31日止年度业绩，收入5704.4万美元，同比增加12.28%;股东应占亏损1881.9万元，同比扩大170.85%;每股基本亏损0.04美元。公告称，收入增长主要是由于集团自2025年12月19日起合并微创®心律管理后自CRM业务录得收入;及随着VitaFlow Liberty®自由•维心流TM及Alwide® Plus敖广®Plus全球商业化持续推进，结构性心脏病业务海外收入较截至2024年12月31日止年度快速增长 255.0%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"微创心通-B(02160)发布年度业绩 股东应占亏损1881.9万元 同比扩大170.85%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02918","02160","BK1574","BK1239","BK1225","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623347972","title":"華昊中天醫藥-B(02563)股份全流通獲聯交所授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2623347972","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623347972?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:26","pubTimestamp":1774888017,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)发布公告，公司已向联交所上市委员会申请批准将由1.48亿股非上市股份转换所得的1.48亿股H股上市及准许买卖。董事会欣然宣布，联交所已于2026年3月20日授出上市批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","BK1161","BK1515","BK1574","02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623134760","title":"《業績》開拓藥業(09939.HK)全年虧損擴至2億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2623134760","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623134760?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:17","pubTimestamp":1774887420,"startTime":"0","endTime":"0","summary":"开拓药业－Ｂ(09939.HK) 公布2025年度业绩，收入录得3,262万人民币(下同)，按年增加553.6%。亏损由上年度1.55亿元，扩至2亿元，每股亏损44分。不派末期息。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2025/08/28中期业绩无派息2025/03/26末期业绩无派息2024/08/26中期业绩无派息2024/03/28末期业绩无派息AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200511160928560_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200511160928560_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1514353/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1514353/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1515","CYB","MCNHmain","CNHmain","MUCmain","09939","BK1574","UCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623478333","title":"康希諾生物(06185)公布2025年業績 實現收入約10.59億元 按年增長28.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623478333","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623478333?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:07","pubTimestamp":1774886865,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 公布2025年业绩，收入约10.59亿元，同比增长28.43%;年内利润2787.3万元，同比扭亏为盈;每股盈利0.11元。自2022年推出四价流脑结合疫苗曼海欣和二价流脑结合疫苗美奈喜以来，两款疫苗为预防婴幼儿流脑疾病提供了更为高效、优质的疫苗选择。2025年，随着流脑疫苗产品的推广和市场导入，两款流脑结合疫苗实现销售收入约9.677亿元，同比增长21.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)公布2025年业绩 实现收入约10.59亿元 同比增长28.43%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1515","BK1191","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623434187","title":"和鉑醫藥-B(02142)公布2025年業績 税後溢利9222.1萬美元 按年增長約32.63倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2623434187","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623434187?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:49","pubTimestamp":1774882160,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布2025年业绩，收入约1.58亿美元，同比增长314.63%;年内溢利9222.1万美元，同比增长约32.63倍;基本每股盈利0.12美元。于2025年，公司全面迈入3.0战略阶段，由三大增长引擎协同驱动：将诺纳生物打造为AI驱动的全球抗体药物发现“新基建”;与跨国制药公司建立长期、平台化的战略合作伙伴关系，以加速全球扩张;通过Harbour Therapeutics实现在自免、肿瘤等领域的中后期资产全球价值的最大化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"和铂医药-B(02142)公布2025年业绩 税后溢利9222.1万美元 同比增长约32.63倍","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623834675","title":"億騰嘉和(06998)3月30日斥資65.88萬港元回購25.45萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623834675","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623834675?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:16","pubTimestamp":1774880212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年3月30日斥资65.88万港元回购25.45万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","06998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346987","title":"歐康維視生物-B(01477)：OT-211 III期臨床試驗完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346987","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623346987?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:05","pubTimestamp":1774879506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-211 在中国开展的III期临床试验已完成首例患者入组。OT-211 为一种 0.003%浓度滴眼液配方，亦为首款获美国食品药品监督管理局批准用于治疗干眼症的TRPM8激动剂。首例患者成功入组标志着OT-211在中国的临床开发取得重要里程碑进展，并体现了集团致力于为DED患者推进创新疗法。OT-211 已于2025年5月 28日获FDA批准用于治疗DED的体征及症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1191","III","BK1574","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193648759","title":"和鉑醫藥-B公布2025財年業績：持續全球合作夯實長期增長根基","url":"https://stock-news.laohu8.com/highlight/detail?id=1193648759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193648759?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 21:55","pubTimestamp":1774878918,"startTime":"0","endTime":"0","summary":"和铂医药-B发布2025财年完整财务报告，显示公司通过持续深化的全球战略合作，为长期可持续发展奠定了坚实基础。全球多中心临床研究项目稳步推进，跨境技术平台协同效应显著增强，共同推动创新管线价值加速释放。公司管理层表示，将继续依托自主知识产权的抗体技术平台，构建开放共赢的全球创新生态。亚洲及欧美市场临床数据持续产出，为后续商业化提供强有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858349","title":"和鉑醫藥公布2025年度業績：常態化全球合作構築業績增長基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858349","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623858349?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 21:53","pubTimestamp":1774878780,"startTime":"0","endTime":"0","summary":"未来，和铂医药将持续深化源头创新，加速助力新一代生物疗法研发，为全球患者带来变革性疗法。此外，公司于2024年11月向NMPA递交HBM9378针对慢性阻塞性肺疾病的IND申请，并于2025年1月获得批准。2025年7月，Windward Bio启动全球II期POLARIS临床研究，旨在评估 HBM9378/WIN378 的长效给药方式对哮喘患者的疗效。2025年12月，NMPA受理了HBM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4921935_ZH21935_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","02142","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623457310","title":"牛散趙建平連續重倉！創新藥迎來配置時點！","url":"https://stock-news.laohu8.com/highlight/detail?id=2623457310","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623457310?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 20:35","pubTimestamp":1774874100,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　今日，A股市场迎来结构性行情，医药板块率先发力，成为当日市场最具活力的赛道之一。　　2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。如盟科药业的前十大股东中则继续出现了赵建平与赵吉的身影，这已是赵建平、赵吉连续5个季度对公司公开重仓。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-03-30/doc-inhsuquq3871370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":8,"totalSize":382,"code":"91000000","status":"200"}]}}